Iodide transport and breast cancer

Poole, Vikki L.; McCabe, Christopher

doi:10.1530/joe-15-0234

Cited by 19 publications

(21 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since I-131 is concentrated by the sodium iodide symporter and that molecule is expressed in the mammary gland ( 6 ), the female breast may receive relevant radiation doses between 0.2 and 2 Gy from repeated courses, with cumulative activities of 1–15 GBq ( 7 ). Based on the recently introduced radiation risk assessment tool of the United States National Cancer Institute, a dose of 2 Gy to the breast of a 10-year-old girl hypothetically doubles her lifetime risk for breast cancer, whereas in a 50-year-old woman, the risk increases only by 20% ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey

Reiners

Schneider

Platonova³

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Published studies on the risk of radiation-induced second primary malignancy (SPM) after radioiodine treatment (RAI) of differentiated thyroid cancer (DTC) refer mainly to patients treated as middle-aged or older adults and are not easily generalizable to those treated at a younger age. Here we review available literature on the risk of breast cancer as an SPM after RAI of DTC with a focus on females undergoing such treatment in childhood, adolescence, or young adulthood. Additionally, we report the results of a preliminary international survey of patient registries from academic tertiary referral centers specializing in pediatric DTC. The survey sought to evaluate the availability of sufficient patient data for a potential international multicenter observational case-control study of females with DTC given RAI at an early age. Our literature review identified a bi-directional association of DTC and breast cancer. The general breast cancer risk in adult DTC survivors is low, ∼2%, slightly higher in females than in males, but presumably lower, not higher, in those diagnosed as children or adolescents than in those diagnosed at older ages. RAI presumably does not substantially influence breast cancer risk after DTC. However, data from patients given RAI at young ages are sparse and insufficient to make definitive conclusions regarding age dependence of the risk of breast cancer as a SPM after RAI of DTC. The preliminary analysis of data from 10 thyroid cancer registries worldwide, including altogether 6,449 patients given RAI for DTC and 1,116 controls, i.e., patients not given RAI, did not show a significant increase of breast cancer incidence after RAI. However, the numbers of cases and controls were insufficient to draw statistically reliable conclusions, and the proportion of those receiving RAI at the earliest ages was too low.In conclusion, a potential international multicenter study of female patients undergoing RAI of DTC as children, adolescents, or young adults, with a sufficient sample size, is feasible. However, breast cancer screening of a larger cohort of DTC patients is not unproblematic for ethical reasons, due to the likely, at most slightly, increased risk of breast cancer post-RAI and the expected ∼10% false-positivity rate which potentially produced substantial "misdiagnosis."

show abstract

Section: Introductionmentioning

confidence: 99%

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey

Reiners

Schneider

Platonova³

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…According to literature, the incidence rates of breast cancer are higher in developed countries than those in developing countries [2]. It is estimated that about 3.2 million people will be diagnosed with breast cancer each year by 2050 worldwide [3]. Breast cancer is a complex and multifactorial disease, which is affected by combined effects of environmental and inherited factors [4].…”

mentioning

confidence: 99%

Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging

Xu¹,

Zhang²

2017

neo

View full text Add to dashboard Cite

This study aims to investigate the predictive values of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in evaluating the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer. Between September 2011 and December 2014, a total of 174 patients with locally advanced breast cancer treated with NAC were selected for this study. Conventional CT and MRI examinations (DWI and DCE-MRI) were performed in all patients before NAC (T0), after the first course (T1) and after the whole course (T2) of NAC. According to the response evaluation criteria in solid tumors (RECIST), patients were divided into the effective [complete response (CR) + partial response (PR)] and ineffective groups [stable disease (SD) + disease progression (DP)]. The Apparent diffusion coefficient (ADC), maximum tumor diameter, the early-phase enhancement rate (Ee), maximal enhanced rate of tumor (E max), maximal linear slope (S max), maximal excretion rate (E wash), signal intensity (SI), maximal signal rise velocity (V max) and area under the curve (AUC) of Cho before and after NAC were calculated. Receiver operating characteristic (ROC) curve was drawn and the AUC of change rate of ADC values and semi-quantitative parameter were utilized to analyze the diagnostic performance of them for evaluating the efficacy of NAC for breast cancer. There were 135 patients in the effective group, with 52 cases of CR and 83 cases of PR; 39 patients were in the ineffective group, with 14 cases of PD and 25 cases of SD. The effective rate of NAC for breast cancer was 77.6%. The ADC values of the two groups significantly increased but the maximum tumor diameter, E e, E max, S max, E wash and AUC of Cho greatly decreased. The effective group had higher ADC values, its change rate and tumor regression rate than the ineffective group. However, the maximum tumor diameter, E e, E max, S max, E wash, AUC of Cho, SI and V max in the effective group were remarkably lower than those in the ineffective group. The change rate of ADC mean achieved the highest evaluation efficiency with AUC of 0.920, sensitivity of 80.0% and specificity of 94.9%. The optimal critical value was 36.49 (× 10-3mm2/s). In conclusion, these results demonstrated that the change rate of ADC mean values and E e could be promising tools for evaluating the efficacy of NAC in patients with breast cancer.

show abstract

“…NIS expression is shown in carcinomas of the prostate, ovary, lung, colon, endometrium, and breast [125,126]. Since NIS expression has been found by immunohistochemistry in about 80% of human breast cancers, there is a growing interest in employing RAI in the treatment of breast cancer [127].…”

Section: Benign and Malignant Tumorsmentioning

confidence: 99%

Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer

Ozomaro

Flavell

et al. 2021

Curr Radiol Rep

View full text Add to dashboard Cite

Purpose Radioactive iodine (RAI) whole-body scan is a sensitive imaging modality routinely used in patients with differentiated thyroid cancer to detect persistent and recurrent disease. However, there can be false-positive RAI uptake that can lead to misdiagnosis and misclassification of a patient’s cancer stage. Recognizing the causes of false positivity can avoid unnecessary testing and treatment as well as emotional stress. In this review, we discuss causes and summarize various mechanisms for false-positive uptake. Recent Findings We report a patient with differentiated thyroid cancer who was found to have Mycobacterium avium complex infection as the cause of false-positive RAI uptake in the lungs. Using this case example, we discuss and summarize findings from the literature on etiologies of false-positive RAI uptake. We also supplement additional original images illustrating other examples of false RAI uptake. Summary False-positive RAI uptake may arise from different causes and RAI scans need to be interpreted in the context of the patient’s history and corresponding cross-sectional imaging findings on workup. Understanding the potential pitfalls of the RAI scan and the mechanisms underlying false uptake are vital in the care of patients with differentiated thyroid cancer.

show abstract

Iodide transport and breast cancer

Cited by 19 publications

References 101 publications

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey

Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging

Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer

Contact Info

Product

Resources

About